In preclinical studies with orthotopic malignant glioma xenografts, pharmacological SHH pathway inhibition significantly improved survival rates by targeting CD133 + tumour-initiating cells responsible for tumour initiation and maintenance [152]. The gene discussed is SHH; the disease is neoplasm.